AtriCure (NASDAQ:ATRC) Director Sven Wehrwein Sells 5,033 Shares

AtriCure, Inc. (NASDAQ:ATRC) Director Sven Wehrwein sold 5,033 shares of AtriCure stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $37.32, for a total value of $187,831.56. Following the sale, the director owned 34,374 shares of the company’s stock, valued at approximately $1,282,837.68. This represents a 12.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Sven Wehrwein also recently made the following trade(s):

• On Tuesday, November 25th, Sven Wehrwein sold 4,967 shares of AtriCure stock. The stock was sold at an average price of $38.00, for a total value of $188,746.00.

AtriCure Trading Down 6.4%

Shares of ATRC stock traded down $2.45 on Wednesday, reaching $36.03. 677,169 shares of the stock were exchanged, compared to its average volume of 552,172. The stock has a market cap of $1.79 billion, a P/E ratio of -59.06 and a beta of 1.56. The company has a quick ratio of 2.83, a current ratio of 3.94 and a debt-to-equity ratio of 0.16. AtriCure, Inc. has a 1-year low of $28.29 and a 1-year high of $43.11. The firm has a 50 day moving average of $35.12 and a two-hundred day moving average of $34.21.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.10. The business had revenue of $134.27 million for the quarter, compared to the consensus estimate of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.56%. The business’s revenue for the quarter was up 15.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. On average, research analysts anticipate that AtriCure, Inc. will post -0.6 EPS for the current year.

Institutional Trading of AtriCure

A number of large investors have recently modified their holdings of ATRC. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in AtriCure by 170.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,196,914 shares of the medical device company’s stock valued at $70,872,000 after purchasing an additional 1,385,544 shares during the period. Nuveen LLC acquired a new stake in AtriCure in the 1st quarter valued at approximately $30,666,000. Wellington Management Group LLP raised its stake in AtriCure by 8.1% during the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company’s stock valued at $151,296,000 after acquiring an additional 322,818 shares in the last quarter. Osterweis Capital Management Inc. acquired a new position in AtriCure during the 1st quarter worth $9,536,000. Finally, Millennium Management LLC boosted its position in AtriCure by 79.2% during the 1st quarter. Millennium Management LLC now owns 623,323 shares of the medical device company’s stock worth $20,108,000 after acquiring an additional 275,487 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on ATRC shares. Needham & Company LLC increased their price objective on shares of AtriCure from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, October 8th. Wall Street Zen upgraded AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. BTIG Research set a $54.00 price objective on AtriCure in a research note on Wednesday, July 30th. Finally, Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research note on Thursday, October 30th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $52.22.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.